Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P6 versus Herceptin in HER2-positive early breast cancer
2013-004525-84Phase 3Completed
- Sponsor
- Celltrion
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab in breast cancer (2 arms), sponsored by Celltrion. Primary endpoint: pathological complete response. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004525-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004525-84.